237 related articles for article (PubMed ID: 31569282)
1. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
Satapathy S; Mittal BR; Bhansali A
Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
[TBL] [Abstract][Full Text] [Related]
2. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
3.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
5. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Satapathy S; Mittal BR
Nucl Med Commun; 2019 Dec; 40(12):1195-1203. PubMed ID: 31658219
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
[TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
[TBL] [Abstract][Full Text] [Related]
10. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of
Zhang J; Song Q; Cai L; Xie Y; Chen Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
[TBL] [Abstract][Full Text] [Related]
12. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.
Kim SJ; Pak K; Koo PJ; Kwak JJ; Chang S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1964-70. PubMed ID: 26253273
[TBL] [Abstract][Full Text] [Related]
14. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
15. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
Alsadik S; Yusuf S; Al-Nahhas A
Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
[TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
Puranik AD; Kulkarni HR; Singh A; Baum RP
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1223-30. PubMed ID: 25822655
[TBL] [Abstract][Full Text] [Related]
18. Pheochromocytomas and paragangliomas.
Yen K; Lodish M
Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis.
Su D; Yang H; Qiu C; Chen Y
Front Oncol; 2023; 13():1141648. PubMed ID: 37483516
[TBL] [Abstract][Full Text] [Related]
20. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
